LPA groups display vastly different outcomes.

Slides:

Advertisements

Similar presentations

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Quality of Life After Treatment of Laryngeal.

Advertisements

Volume 42, Issue 5, Pages (May 2005)

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Triangles and dotted lines are for mean values. , P <

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Clinical Epidemiology and Global Health

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

Volume 61, Issue 5, Pages (November 2014)

The Impact of Pain Management on Quality of Life

Five-year real world outcomes of GeoForm ring implantation in patients with ischemic mitral regurgitation Tomasz A. Timek, MD, Robert L. Hooker, MD,

Effects of deep hypothermic circulatory arrest on outcome after resection of ascending aortic aneurysm Franz F Immer, MD, Hanna Barmettler, MD, Pascal.

Health-Related Quality of Life Outcome After On-Pump Versus Off-Pump Coronary Artery Bypass Graft Surgery: A Prospective Randomized Study Reza Motallebzadeh,

Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,

Health Status Rated With the Medical Outcomes Study 36-Item Short-Form Health Survey After Spinal Cord Injury Mark J. Haran, Bonsan B. Lee, Madeleine.

Volume 44, Issue 3, Pages (March 2006)

Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,

Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity Nina K. Grewal,

Long-Term Health-Related Quality of Life After Maze Surgery for Atrial Fibrillation Catharina Lundberg, MD, Anders Albåge, MD, PhD, Carina Carnlöf, RN,

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Laila Hellgren, MD, Elisabeth Ståhle, MD, PhD

Comparison of recovery after mitral valve repair and replacement

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Mu Qin et al. JACEP 2017;j.jacep

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Clinical Epidemiology and Global Health

Health-related quality of life in survivors of open ruptured abdominal aortic aneurysm repair: A matched, controlled cohort study Andrew B. Hill, MDCM,

Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Health-Related Quality of Life in Patients Attending a Gastroenterology Outpatient Clinic: Functional Disorders Versus Organic Diseases Magnus Simrén,

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

Quality of life of patients with Takayasu’s arteritis

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Clinical response in patients with early and established RA at month 24. *p

Patient-reported quality of life after abdominal aortic aneurysm surgery: A prospective comparison of endovascular and open repair Badr Aljabri, MD,

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Kaplan-Meier One Minus Survival plot showing cumulative progression to clinical arthritis for patients with clinically suspect arthralgia divided in four.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment Ralf W. Sprengers, MD, Martin Teraa,

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Multivariable analysis of Clinical Disease Activity Index (CDAI) over time modelled with a cubic effect of time and adjusted for age, gender, disease duration,

Quality of life after aortic valve replacement with tissue and mechanical implants Artyom Sedrakyan, MD, Patricia Hebert, PhD, Viola Vaccarino, MD, PhD,

J. J. Smith, FRCS, A. M. Garratt, PhD, M. Guest, FRCS, R. M

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Satisfaction with control of RA

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

Summary multiple regression charts for (A) PROFAD physical fatigue and (B) PROFAD mental fatigue scores. Summary multiple regression charts for (A) PROFAD.

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

LPA groups display vastly different outcomes. LPA groups display vastly different outcomes. (A) Functional disability (HAQ-DI), pain, fatigue and depression (PHQ-9) scores. (B) Physical and mental component scores across LPA groups. (C) Health-related quality of life individual domain scores across LPA groups and age-matched and gender-matched controls. (D) Work productivity and activity impairment scores across LPA groups. Values represent estimated marginal means; analysis of covariance adjusted for age, gender, disease duration, fibromyalgia and presence of irreversible articular damage. All pairwise comparisons are Benjamini-Hochberg corrected. Different subscript letters denote groups that differ significantly (p<0.05). All pairwise comparisons are Benjamini-Hochberg-corrected; values not sharing subscript letters denote subgroups whose averages differ significantly (p<0.05). BP, bodily pain; GH, general health; MDGA, physician global assessment of disease activity; MH, mental health; PF, physical function; PtGA, patient global assessment of disease activity; RE, role emotional; RP, role physical; SF, social function; SF36-MCS, Short Form 36 mental component score; SF36-PCS, Short Form 36 physical component score. George A Karpouzas et al. RMD Open 2018;4:e000695 Copyright © BMJ Publishing Group & EULAR. All rights reserved.